Welcome to our dedicated page for Cardiol Therapeutics SEC filings (Ticker: CRDL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cardiol Therapeutics Inc. filings document the formal disclosures of a Canadian life sciences issuer listed on Nasdaq and the TSX. Recent Form 6-K reports furnish press releases and exhibits covering CardiolRx clinical programs, including MAVERIC in recurrent pericarditis and ARCHER in acute myocarditis, as well as CRD-38 development, patent updates, and operating results summarized with audited financial statements and management discussion.
The filing record also documents governance and capital-structure matters, including annual general meeting notices, Class A common share voting mechanics, bought deal private placement terms, underwriting agreements, and warrant indenture provisions. These filings describe the company’s securities, financing arrangements, clinical-development disclosures, and foreign-issuer reporting framework.
Cardiol Therapeutics Inc. entered into a bought deal private placement, with a sole underwriter agreeing to purchase for resale 10,384,616 units at $1.30 per unit for gross proceeds of $13.5 million. The company also granted the underwriter a 10% option for up to 1,038,462 additional units at the same price to cover over-allotments.
Each unit includes one common share and one-half warrant, with each whole warrant exercisable at $1.75 per share for 24 months from issuance. Cardiol plans to use the net proceeds to advance its research and clinical development programs, and for general and administrative expenses, working capital, and other expenses.
The offering is expected to close on or about January 23, 2026, subject to conditions including TSX approval and completion of an underwriting agreement, and will be conducted under Canadian prospectus exemptions, including the Listed Issuer Financing Exemption.
Cardiol Therapeutics reports that its pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis has surpassed 50% patient enrollment, marking a key execution and risk‑reduction milestone for its lead registrational program. More than 15 leading cardiovascular centers in the United States are actively enrolling patients, with additional top-tier sites in Europe and Canada being activated, and the company expects full enrollment to be completed in Q2 2026.
MAVERIC is designed to enroll approximately 110 patients across about 25 centers in North America and Europe, with a primary endpoint of freedom from a new recurrent pericarditis episode after six months of double-blind treatment. The trial builds on positive Phase II MAvERIC-Pilot data showing rapid and sustained reductions in pain, inflammation, and recurrence rates, and on Phase II ARCHER data in myocarditis. Cardiol also highlights Orphan Drug Designation for CardiolRx™ in pericarditis and ongoing development of CRD-38 for inflammatory heart disease, including heart failure.
Cardiol Therapeutics (CRDL) furnished a Form 6-K that includes a news release stating it received a U.S. patent allowance broadly protecting its heart drugs to late 2040. The exhibit is a news release dated November 13, 2025.
The company indicates it files annual reports under cover of Form 40-F as a foreign private issuer.
Cardiol Therapeutics Inc. filed a Form F-10 base shelf registration to offer up to US $150,000,000 of securities under the MJDS. The shelf covers Common Shares, Debt Securities, Warrants, Subscription Receipts, and Units, to be sold from time to time during the 25-month period the prospectus remains effective, with specific terms to be set in prospectus supplements.
Amendment No. 1 adds that one or more selling securityholders may conduct secondary offerings by prospectus supplement, and the aggregate amount available for the company’s sales will be reduced by the aggregate amount of such secondary offerings. Cardiol’s Common Shares trade on the TSX and Nasdaq under “CRDL”.
Cardiol Therapeutics Inc. filed a Form 6-K as a foreign private issuer that reports under Form 40-F. The filing mainly furnishes a news release dated November 5, 2025, announcing that results from its Phase II ARCHER clinical trial will be presented at the European Society of Cardiology’s Scientific Meeting on Myocardial & Pericardial Diseases.
Cardiol Therapeutics (CRDL) filed a Form 6-K furnishing a news release as Exhibit 99.1. The exhibit, dated October 21, 2025, states the company completed a US$11.4 million financing and extended its cash runway into Q3 2027.
This is an informational submission under the Exchange Act for foreign private issuers and directs readers to the attached news release for details.
Cardiol Therapeutics (CRDL) furnished a Form 6‑K that includes a news release titled “Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027.” The filing signals that the company has secured US$11 million in financing, which the company states extends its cash runway into Q3 2027. Details of the structure or terms are contained in the referenced news release.